Limits...
Evaluation of a Novel Herbal Immunomodulator Drug (IMOD) in Treatment of Experimental Canine Visceral leishmaniasis.

Malmasi A, Ziaie Ardestani B, Mohebali M, Akhoundi B, Ziaie S, Masoudifard M, Khorram Khorshid H, Nasiri M, Bayanolhagh S, Mostafavi E, Delrobai M, Siavashi V - Iran J Pharm Res (2014)

Bottom Line: Physical examination, hematological, biochemical, serological, parasitological, pathological and imaging evaluations were performed pre-/post- interventions every month for 3 months.Comparing with control groups (I&V), immune-chemotherapy group (Glucantime® plus IMOD) showed significantly higher efficacy in resolving the clinical signs and hematobiochemistry factors.Based on our results, using IMOD in combination with meglumine antimoniate (Glucantime®) has significantly improved CVL than the latter drug alone.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.

ABSTRACT
Toxicity and drug resistance against pentavalent antimonials, medications of choice in treatment of leishmaniasis for more than 5 decades, have become important subjects globally. This study was a randomized, open labeled trial that was designed to determine efficacy and safety of IMOD as a novel herbal immunomodulator drug for treatment of canine visceral leishmaniasis (CVL). Twenty healthy mongrel dogs were infected with Iranian strain of L. Infantum amastigotes and randomly divided to 5 groups with four animals for each included on: I: negative control (non-infected) II: Glucantime® III: Glucantime® plus IMOD (immune-chemotherapy) IV: IMOD and V: positive control (non-treated). Physical examination, hematological, biochemical, serological, parasitological, pathological and imaging evaluations were performed pre-/post- interventions every month for 3 months. Comparing with control groups (I&V), immune-chemotherapy group (Glucantime® plus IMOD) showed significantly higher efficacy in resolving the clinical signs and hematobiochemistry factors. Based on our results, using IMOD in combination with meglumine antimoniate (Glucantime®) has significantly improved CVL than the latter drug alone. So, it seems this new herbal medicine is useful as adjuvant therapy for canine visceral leishmaniasis.

No MeSH data available.


Related in: MedlinePlus

Agarose gel electrophoresis, showing PCR-RFLP results. Lane 1: Leishmania major; lanes 2-4: L. tropica; lane 5: negative control; lanes 6 and 7: L. infantum; M: molecular weight marker
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4232802&req=5

Figure 1: Agarose gel electrophoresis, showing PCR-RFLP results. Lane 1: Leishmania major; lanes 2-4: L. tropica; lane 5: negative control; lanes 6 and 7: L. infantum; M: molecular weight marker

Mentions: Donor dog was diagnosed by clinical examination and rK39 dipstick (DiaMed-IT LEISH, Belgium) (40). Definitive diagnosis achieved by serological screening (DAT) followed by bone marrow puncture and parasitological confirmation. Isolated parasite was identified as L. Infantum by PCR-RFLP technique using primers derived ITS1 gene and HaeIII restricted enzyme (Figure 1) (41).


Evaluation of a Novel Herbal Immunomodulator Drug (IMOD) in Treatment of Experimental Canine Visceral leishmaniasis.

Malmasi A, Ziaie Ardestani B, Mohebali M, Akhoundi B, Ziaie S, Masoudifard M, Khorram Khorshid H, Nasiri M, Bayanolhagh S, Mostafavi E, Delrobai M, Siavashi V - Iran J Pharm Res (2014)

Agarose gel electrophoresis, showing PCR-RFLP results. Lane 1: Leishmania major; lanes 2-4: L. tropica; lane 5: negative control; lanes 6 and 7: L. infantum; M: molecular weight marker
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4232802&req=5

Figure 1: Agarose gel electrophoresis, showing PCR-RFLP results. Lane 1: Leishmania major; lanes 2-4: L. tropica; lane 5: negative control; lanes 6 and 7: L. infantum; M: molecular weight marker
Mentions: Donor dog was diagnosed by clinical examination and rK39 dipstick (DiaMed-IT LEISH, Belgium) (40). Definitive diagnosis achieved by serological screening (DAT) followed by bone marrow puncture and parasitological confirmation. Isolated parasite was identified as L. Infantum by PCR-RFLP technique using primers derived ITS1 gene and HaeIII restricted enzyme (Figure 1) (41).

Bottom Line: Physical examination, hematological, biochemical, serological, parasitological, pathological and imaging evaluations were performed pre-/post- interventions every month for 3 months.Comparing with control groups (I&V), immune-chemotherapy group (Glucantime® plus IMOD) showed significantly higher efficacy in resolving the clinical signs and hematobiochemistry factors.Based on our results, using IMOD in combination with meglumine antimoniate (Glucantime®) has significantly improved CVL than the latter drug alone.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.

ABSTRACT
Toxicity and drug resistance against pentavalent antimonials, medications of choice in treatment of leishmaniasis for more than 5 decades, have become important subjects globally. This study was a randomized, open labeled trial that was designed to determine efficacy and safety of IMOD as a novel herbal immunomodulator drug for treatment of canine visceral leishmaniasis (CVL). Twenty healthy mongrel dogs were infected with Iranian strain of L. Infantum amastigotes and randomly divided to 5 groups with four animals for each included on: I: negative control (non-infected) II: Glucantime® III: Glucantime® plus IMOD (immune-chemotherapy) IV: IMOD and V: positive control (non-treated). Physical examination, hematological, biochemical, serological, parasitological, pathological and imaging evaluations were performed pre-/post- interventions every month for 3 months. Comparing with control groups (I&V), immune-chemotherapy group (Glucantime® plus IMOD) showed significantly higher efficacy in resolving the clinical signs and hematobiochemistry factors. Based on our results, using IMOD in combination with meglumine antimoniate (Glucantime®) has significantly improved CVL than the latter drug alone. So, it seems this new herbal medicine is useful as adjuvant therapy for canine visceral leishmaniasis.

No MeSH data available.


Related in: MedlinePlus